Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Des Deliv ; 6(1): 15-28, 1990 May.
Article in English | MEDLINE | ID: mdl-2078285

ABSTRACT

A dihydropyridine in equilibrium with pyridinium salt redox system was applied to effect brain delivery of gamma-aminobutyric acid (GABA) derivatives and analogues. The redox system allows the lipophilic dihydropyridine conjugates to penetrate the blood brain barrier, whereas corresponding oxidized pyridinium forms are retained in the brain for an extended period and rapidly eliminated from the periphery. The most promising compound was the GABA benzyl ester-CDS (1a, Scheme I). It had an ED50 of 15.8 mg/kg (i.v.) in protecting mice against maximal electroconvulsive shock-induced tonic hind-leg extension.


Subject(s)
Anticonvulsants/administration & dosage , Brain/drug effects , gamma-Aminobutyric Acid/analogs & derivatives , Animals , Anticonvulsants/chemical synthesis , Anticonvulsants/pharmacokinetics , Blood-Brain Barrier , Drug Carriers , Drug Design , Half-Life , Humans , Hydrolysis , Membranes/drug effects , Mice , Oxidation-Reduction , Rats , Rats, Inbred Strains , Tissue Distribution , gamma-Aminobutyric Acid/administration & dosage , gamma-Aminobutyric Acid/chemical synthesis , gamma-Aminobutyric Acid/pharmacokinetics
2.
Psychopharmacology (Berl) ; 92(2): 157-63, 1987.
Article in English | MEDLINE | ID: mdl-2885884

ABSTRACT

We evaluated the anxiolytic property of a brain-specific gamma-aminobutyric acid delivery system (GABA-CDS) in male rats by means of a drink-foot shock conflict procedure. Brain-specific delivery of the active compound was achieved by combination of GABA benzyl ester with an interconvertible dihydropyridine in equilibrium pyridinium salt carrier, which is "locked in" to the brain upon its oxidation. Pharmacokinetic studies revealed that the hydrophilic pyridinium salt form (G-Q+) of the GABA-CDS formed in situ remained in the brain for 12 h but was cleared from the blood and other peripheral tissues by 0.5-4 h. While the lipophilic form (G-DH) of the GABA-CDS caused a marked and sustained anxiolytic response when administered systemically, GABA and the charged pyridinium salt (G-Q+ form) of the GABA-CDS were ineffective. G-DH was injected at either 0, 4, 10 or 25 mg/kg IV in DMSO after rats were water and food deprived. After either 0.5, 2, 4, 8 or 24 h, rats were permitted 10 s of shock-free drinking of 10% sucrose, then given a 35 mA (DC) current through the drinking tube. Drinking time was recorded for 3 min. All doses of G-DH caused a significant increase in anxiolysis over control levels through 8 h. An increase (4 to 7-fold) in anxiolytic activity was observed through the 10 mg/kg dose with the 25 mg/kg dose causing no additional increase. No sedation or analgesia was observed at 2 h with any anxiolytic-producing dose of G-DH. These results suggest that G-DH elicits anxiolysis with minimal sedation, through the local brain action the G-Q+ or subsequent to the release of GABA.


Subject(s)
Anti-Anxiety Agents , gamma-Aminobutyric Acid/pharmacology , Animals , Drug Implants , Male , Rats , Rats, Inbred Strains , Reaction Time/drug effects , Tissue Distribution , gamma-Aminobutyric Acid/administration & dosage , gamma-Aminobutyric Acid/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...